ArticleBone marrow transplantation2008
Delayed lymphocyte infusion in children given SCT.
Article in Bone marrow transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients.Bone marrow transplantation · 2015Article
- Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft.Bone marrow transplantation · 2012Article
- Prevention of GVHD without losing GVL effect: windows of opportunity.Immunologic research · 2011Review
- Article
- Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis.Bone marrow transplantation · 2010Article
- Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Immunotherapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of DLI can change chimerism and prevent rejection and relapse. However, the prerequisite for a successful use of this powerful and potentially harmful tool is a minimal burden with resting leukemia or in the case of nonmalignant disease autologous cells. Therefore, a monitoring of the hematopoietic chimerism and of the post-transplant MRD is recommended with a narrow (best: weekly) time schedule. Also, using low and increasing numbers of DLI, a GvHD can be avoided or even minimized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.